Pharmaceutical Sweden’s BioArctic saw its shares rise 6.53% to 79.90 Swedish kronor by mid-morning, following its announcement after markets closed on Monday that it had received a 15 million-euro ($16.7 million) payment from its partner Eisai for the achievement of the first patient being dosed in the global, single confirmatory Phase III study (Clarity AD) with BAN2401 in early Alzheimer´s disease. 21 May 2019